Novartis Ag

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Xiaodong Lin

Rajinder Paul Singh

Manoj C Desai

Liya Chen

Verena D Huebner

Beata Krywult

Ian James

Liang Wang

Robert Lowell Simmons

Qingming Zhu

Folkert Reck

Virender Singh Aulakh

Anthony Casarez

Rob Trainor

Thayalan Navaratnam

Jennifer C Moore

Keith Bruce Pfister

Paul Andrew Barsanti

Yasheen Zhou

Alice C Rico

Jacob J Plattner

Daniel T Chu

Zachary Kevin Sweeney

Martin Sendzik

James Clifford Sutton

Matthew T Burger

Oliver L Saunders

Mika Lindvall

Martijn Fenaux

Heinz Ernst Moser

Cheng Hu

Aregahegn Yifru

Lifeng Wan

Fumiaki Yokokawa

Yue Pan

Meiliana Tjandra

Sampath-Kumar Anandan

Robert F Keyes

Jeff Xianming Jin

Liang Mao

Glenn McEnroe

Guido Koch

Weidong Zhong

Markus Furegati

Robert Kucejko

Georgia Law Carroll

Alice Rico

Flavio Ossola

Paul A Renhowe

Daniel J Poon

Weibo Wang

Savithri Ramurthy

Cynthia Shafer

Christopher McBride

Allan S Wagman

Sharadha Subramanian

Yi Xia

Simon C Ng

Timothy D Machajewski

Rama Jain

Barry Haskell Levine

Annette Olga Walter

Xiaojing Michael Wang

Abran Q Costales

Kris Mendenhall

Payman Amiri

Robert L Warne

Nathan Brammeier

Teresa E Pick

Jeffrey H Dove

Mina E Aikawa

Maureen McKenna

William R Antonios-McCrea

Johanna M Jansen

Wei Shu

Ann B Jefferson

Zhenhai Gao

Kristin Brinner

X Michael Wang

Brandon M Doughan

Stephen E Basham

Jeremy M Murray

Xiaojong M Wang

Glenn Mcenroe

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains. 

Beta-lactamase inhibitors

This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

Monobactam organic compounds for the treatment of bacterial infections

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R, R, R, R, Rand Z are defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

2'-ethynyl nucleoside derivatives for treatment of viral infections

The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R, R, R, R, Rand Z are as defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

2'-Ethynyl nucleoside derivatives for treatment of viral infections

The present invention provides a compound of formula (I): 

Heteroaryl compounds and their uses

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.

The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions. 

Quinazolines for PDK1 inhibition

Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones

The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: 

Substituted 2,5-heterocyclic derivatives

Antimicrobial macrolide and ketolide compounds are provided having formulas XII: as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Pyridyl substituted ketolide antibiotics

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

Estrogen receptor modulators

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

C12 modified erythromycin macrolides and ketolides having antibacterial activity

Growing community of inventors

Orinda, CA, United States of America

Xiaodong Lin